Print

Japanese Clinical Trial Concludes Ivermectin Is “Safe and Effective” Treatment of COVID
By Dr. Paul Craig Roberts
Global Research, February 01, 2022

Url of this article:
https://www.globalresearch.ca/japanese-clinical-trial-concludes-ivermectin-safe-effective-treatment-covid/5768876

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), click here.

Visit and follow us on Instagram at @globalresearch_crg.

***

“Ivermectin has the same antiviral effect” on all mutant strains, including Alpha, Delta, and Omicron. Kowa added that ivermectin suppresses invasion of the virus and inhibits its replication.”

As you can see, I have told you the truth about Ivermectin, while Fauci, Biden, CDC, WHO, FDA, NIH, the medical establishment, and the whore Western media and social media tyrants have lied to you through their teeth while censoring those who knew for a fact that Ivermectin was an effective treatment that was being blocked and denied to dying people simply for the sake of Big Pharma profits and the control over people and destruction of civil liberty desired by Western governments and the ruling elites to whom Governments answer.

What we have experienced is not a mistake. We have, and are, experiencing an intentional mass murder event. No one needed to die. The vaccine is not only pointless as a preventative, it itself is a cause of health problems and death. The entire establishment knows this; yet they continue to push vaccination.

Are we going to let these despicable criminals get away with a crime that far exceeds Nazi crimes tried at Nuremberg?

See this (Epoch Times):

A Japanese conglomerate that is studying the anti-parasitic drug ivermectin has found that the medication had an antiviral effect on Omicron, according to joint non-clinical research.

Kowa Co. Ltd., a conglomerate with interests in trading, hospitality, and electronics, along with health and medical applications, issued a press release (pdf) on Jan. 31 stating that ivermectin has been found to be effective against Omicron in in vitro studies. The firm is also in the process of carrying out a Phase 3 clinical trial on the use of ivermectin to treat COVID-19 patients, though the company’s remarks on effectiveness pertain to the findings of lab-based research.

Kowa representatives didn’t respond to a request for comment by press time.

The company, working with Kitasato University based in Tokyo, said that ivermectin has the “same antiviral effect” on all “mutant strains,” including Alpha, Delta, and Omicron. Kowa added that ivermectin suppresses invasion of the virus and inhibits its replication.

“[Ivermectin] is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases,” the report said.

Ivermectin has been used by the World Health Organization for over 30 years to treat parasitic infections. Volunteers have distributed the drug in African countries where it has been found to be extremely effective, said the Kowa report.

However, the treatment has been mired in controversy during recent times as the U.S. Food and Drug Administration (FDA) has not approved the use of ivermectin as a treatment for COVID-19, even though the drug is used in humans to treat a variety of conditions.

The FDA has refused to respond to a Freedom of Information Act request (FOIA) asking for details about any reports of side effects related to the use of ivermectin in treating COVID-19 while publicly denouncing its usage.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @globalresearch_crg. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Dr. Paul Craig Roberts writes on his blog site, PCR Institute for Political Economy, where this article was originally published. He is a regular contributor to Global Research.

Featured image is from Zero Hedge

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article.